{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:25:24Z","timestamp":1772166324108,"version":"3.50.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T00:00:00Z","timestamp":1729814400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T00:00:00Z","timestamp":1729814400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Sichuan Science and Technology Department for Key Research and Development Program","award":["2019YFS0027"],"award-info":[{"award-number":["2019YFS0027"]}]},{"name":"Sichuan Science and Technology Department for Key Research and Development Program","award":["2019YFS0027"],"award-info":[{"award-number":["2019YFS0027"]}]},{"name":"Sichuan Science and Technology Department for Key Research and Development Program","award":["2019YFS0027"],"award-info":[{"award-number":["2019YFS0027"]}]},{"name":"Sichuan Science and Technology Department for Key Research and Development Program","award":["2019YFS0027"],"award-info":[{"award-number":["2019YFS0027"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Agents Cancer"],"DOI":"10.1186\/s13027-024-00617-z","type":"journal-article","created":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T12:01:59Z","timestamp":1729857719000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Real-world clinical features and survival outcomes in diffuse large B-cell lymphoma patients with hepatitis B virus infection"],"prefix":"10.1186","volume":"19","author":[{"given":"Wanxi","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongbing","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caigang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,10,25]]},"reference":[{"issue":"9","key":"617_CR1","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1056\/NEJMra2027612","volume":"384","author":"LH Sehn","year":"2021","unstructured":"Sehn LH, Salles G. Diffuse large B-cell lymphoma. N Engl J Med. 2021;384(9):842\u201358.","journal-title":"N Engl J Med"},{"key":"617_CR2","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.anndiagpath.2017.05.005","volume":"34","author":"C Cao","year":"2018","unstructured":"Cao C, Feng J, Gu H, et al. Distribution of lymphoid neoplasms in Northwest China: analysis of 3244 cases according to WHO classification in a single institution. Ann Diagn Pathol. 2018;34:60\u20135.","journal-title":"Ann Diagn Pathol"},{"issue":"10","key":"617_CR3","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1002\/ajh.21824","volume":"85","author":"SO Yoon","year":"2010","unstructured":"Yoon SO, Suh C, Lee DH, et al. Distribution of lymphoid neoplasms in the Republic of Korea: analysis of 5318 cases according to the world health organization classification. Am J Hematol. 2010;85(10):760\u20134.","journal-title":"Am J Hematol"},{"issue":"77","key":"617_CR4","first-page":"23","volume":"6","author":"QP Yang","year":"2011","unstructured":"Yang QP, Zhang WY, Yu JB, et al. Subtype distribution of lymphomas in Southwest China: analysis of 6,382 cases using WHO classification in a single institution. Diagn Pathol. 2011;6(77):23.","journal-title":"Diagn Pathol"},{"issue":"3","key":"617_CR5","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1002\/ijc.31643","volume":"144","author":"P Mahale","year":"2019","unstructured":"Mahale P, Engels EA, Koshiol J. Hepatitis B virus infection and the risk of cancer in the elderly US population. Int J Cancer. 2019;144(3):431\u20139.","journal-title":"Int J Cancer"},{"issue":"5","key":"617_CR6","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1111\/apt.15132","volume":"49","author":"TH Su","year":"2019","unstructured":"Su TH, Liu CJ, Tseng TC, et al. Chronic hepatitis B is associated with an increased risk of B-cell non-Hodgkin\u2019s lymphoma and multiple myeloma. Aliment Pharmacol Ther. 2019;49(5):589\u201398.","journal-title":"Aliment Pharmacol Ther"},{"issue":"9","key":"617_CR7","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/S1470-2045(10)70167-4","volume":"11","author":"EA Engels","year":"2010","unstructured":"Engels EA, Cho ER, Jee SH. Hepatitis B virus infection and risk of non-Hodgkin lymphoma in South Korea: a cohort study. Lancet Oncol. 2010;11(9):827\u201334.","journal-title":"Lancet Oncol"},{"issue":"6","key":"617_CR8","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1182\/blood-2018-12-894097","volume":"133","author":"W Ren","year":"2019","unstructured":"Ren W, Ye X, Su H, et al. Genetic landscape of hepatitis B virus-associated diffuse large B-cell lymphoma. Blood. 2019;133(6):620. https:\/\/doi.org\/10.1182\/blood-2018-12-894097.","journal-title":"Blood"},{"issue":"Supplement","key":"617_CR9","doi-asserted-by":"publisher","first-page":"S248","DOI":"10.4103\/0973-1482.187285","volume":"14","author":"X Yan","year":"2018","unstructured":"Yan X, Zhou M, Lou Z, et al. Diffuse large B-cell lymphoma with concurrent hepatitis B virus infection in the MabThera era: unique clinical features and worse outcomes. J Cancer Res Ther. 2018;14(Supplement):S248\u201353.","journal-title":"J Cancer Res Ther"},{"issue":"1","key":"617_CR10","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1080\/16078454.2021.2011546","volume":"27","author":"MY Zhang","year":"2022","unstructured":"Zhang MY, Gao F, Zhao YW, Ni BW, Huang HH, Hou J. Inferior survival and frequent hepatic dysfunction in non-Hodgkin\u2019s lymphoma patients with HBV infection: a systematic review and meta-analysis. Hematology. 2022;27(1):70\u20139.","journal-title":"Hematology"},{"issue":"28","key":"617_CR11","doi-asserted-by":"publisher","first-page":"25061","DOI":"10.18632\/oncotarget.4677","volume":"6","author":"L Deng","year":"2015","unstructured":"Deng L, Song Y, Young KH, et al. Hepatitis B virus-associated diffuse large B-cell lymphoma: unique clinical features, poor outcome, and hepatitis B surface antigen-driven origin. Oncotarget. 2015;6(28):25061\u201373.","journal-title":"Oncotarget"},{"issue":"8","key":"617_CR12","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1002\/ijc.33027","volume":"147","author":"M Li","year":"2020","unstructured":"Li M, Shen Y, Chen Y, et al. Characterization of hepatitis B virus infection and viral DNA integration in non-Hodgkin lymphoma. Int J Cancer. 2020;147(8):2199\u2013209.","journal-title":"Int J Cancer"},{"issue":"2","key":"617_CR13","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/s41419-017-0097-1","volume":"9","author":"X Zhao","year":"2018","unstructured":"Zhao X, Guo X, Xing L, et al. HBV infection potentiates resistance to S-phase arrest-inducing chemotherapeutics by inhibiting CHK2 pathway in diffuse large B-cell lymphoma. Cell Death Dis. 2018;9(2):61.","journal-title":"Cell Death Dis"},{"issue":"4","key":"617_CR14","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1111\/ejh.13300","volume":"103","author":"X Zhou","year":"2019","unstructured":"Zhou X, Wuchter P, Egerer G, et al. Role of virological serum markers in patients with both hepatitis B virus infection and diffuse large B-cell lymphoma. Eur J Haematol. 2019;103(4):410\u20136.","journal-title":"Eur J Haematol"},{"key":"617_CR15","doi-asserted-by":"publisher","first-page":"1967648","DOI":"10.1155\/2017\/1967648","volume":"2017","author":"Z Liu","year":"2017","unstructured":"Liu Z, Li S, Guo W, Wang Y, Wang M, Bai O. MYC gene rearrangements are closely associated with poor survival of diffuse large B cell lymphoma with hepatitis B virus infection. Biomed Res Int. 2017;2017:1967648.","journal-title":"Biomed Res Int"},{"key":"617_CR16","doi-asserted-by":"publisher","first-page":"9644576","DOI":"10.1155\/2022\/9644576","volume":"2022","author":"D Cai","year":"2022","unstructured":"Cai D, Zhang D, Hu P, Ren H. A comprehensive hepatitis B surface antigen-positive patient-centered screening and linkage to care strategies targeting microelimination of hepatitis C virus infection in Chongqing, China. Can J Gastroenterol Hepatol. 2022;2022:9644576.","journal-title":"Can J Gastroenterol Hepatol"},{"issue":"9","key":"617_CR17","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.7150\/jca.24384","volume":"9","author":"Y Wang","year":"2018","unstructured":"Wang Y, Wang H, Pan S, et al. Capable infection of hepatitis B virus in diffuse large B-cell lymphoma. J Cancer. 2018;9(9):1575\u201381.","journal-title":"J Cancer"},{"key":"617_CR18","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13027-018-0215-4","volume":"13","author":"YF Guo","year":"2018","unstructured":"Guo YF, Pan JX, Zhuang WH. Concurrent and reactivation of hepatitis B virus infection in diffuse large B-cell lymphoma: risk factors and survival outcome. Infect Agent Cancer. 2018;13:40.","journal-title":"Infect Agent Cancer"},{"issue":"1","key":"617_CR19","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s13027-021-00396-x","volume":"16","author":"DG Chen","year":"2021","unstructured":"Chen DG, Chen G, Wang C, et al. Clinicopathological and prognostic features of hepatitis B virus-associated diffuse large B-cell lymphoma: a single-center retrospective study in China. Infect Agent Cancer. 2021;16(1):57.","journal-title":"Infect Agent Cancer"},{"key":"617_CR20","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/1471-2407-8-115","volume":"8","author":"F Wang","year":"2008","unstructured":"Wang F, Xu RH, Luo HY, et al. Clinical and prognostic analysis of hepatitis B virus infection in diffuse large B-cell lymphoma. BMC Cancer. 2008;8:115.","journal-title":"BMC Cancer"},{"issue":"9","key":"617_CR21","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1634\/theoncologist.2019-0756","volume":"25","author":"CL Cheng","year":"2020","unstructured":"Cheng CL, Huang SC, Chen JH, et al. Hepatitis B surface antigen positivity is an independent unfavorable prognostic factor in diffuse large B-cell lymphoma in the rituximab era. Oncologist. 2020;25(9):793\u2013802.","journal-title":"Oncologist"},{"key":"617_CR22","doi-asserted-by":"publisher","first-page":"1216610","DOI":"10.3389\/fimmu.2023.1216610","volume":"14","author":"X Wan","year":"2023","unstructured":"Wan X, Young KH, Bai O. HBV-associated DLBCL of poor prognosis: advance in pathogenesis, immunity and therapy. Front Immunol. 2023;14:1216610.","journal-title":"Front Immunol"},{"key":"617_CR23","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1016\/j.omtn.2022.01.015","volume":"27","author":"J Li","year":"2022","unstructured":"Li J, Chen Y, Guo X, et al. lncNBAT1\/APOBEC3A is a mediator of HBX-induced chemoresistance in diffuse large B cell lymphoma cells. Mol Ther Nucleic Acids. 2022;27:1064\u201377.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"4","key":"617_CR24","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1200\/JCO.2008.18.0182","volume":"27","author":"W Yeo","year":"2009","unstructured":"Yeo W, Chan TC, Leung NW, et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol. 2009;27(4):605\u201311.","journal-title":"J Clin Oncol"},{"issue":"7","key":"617_CR25","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1038\/sj.bjc.6601699","volume":"90","author":"W Yeo","year":"2004","unstructured":"Yeo W, Zee B, Zhong S, et al. Comprehensive analysis of risk factors associating with hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer. 2004;90(7):1306\u201311.","journal-title":"Br J Cancer"}],"container-title":["Infectious Agents and Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13027-024-00617-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13027-024-00617-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13027-024-00617-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T12:04:18Z","timestamp":1729857858000},"score":1,"resource":{"primary":{"URL":"https:\/\/infectagentscancer.biomedcentral.com\/articles\/10.1186\/s13027-024-00617-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,25]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["617"],"URL":"https:\/\/doi.org\/10.1186\/s13027-024-00617-z","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4822092\/v1","asserted-by":"object"}]},"ISSN":["1750-9378"],"issn-type":[{"value":"1750-9378","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,25]]},"assertion":[{"value":"29 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study protocol was conducted in conformity with the Declaration of Helsinki and was approved by the Ethics Committee of West China Medical College of Sichuan University (approval number: 2024\u2013955). As this study is a retrospective study and patient anonymization, the Ethics Committee has determined to be exempt from signing informed consent forms.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All the authors declare no actual or potential conflict of interest with this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"55"}}